© 2022 MJH Life Sciences and Contagion Live. All rights reserved.
© 2022 MJH Life Sciences™ and Contagion Live. All rights reserved.
September 22, 2022
This will include 3 trials to examine the therapy in different formulations in HIV studies.
September 19, 2022
Gender-affirming hormone therapy (GAHT) therapy consists of administration of exogenous hormones and suppression of endogenous hormone production, with the goal of obtaining characteristics more congruent with an individual’s gender identity. Here is a review of these therapies and consideration for PrEP and the risks associated with HIV in this diverse population.
September 15, 2022
There are a number of programs designed to help lower rates of infection and transmission amongst this industry's workforce in South Africa.
September 14, 2022
Pregnant people taking dolutegravir were more likely to achieve HIV viral suppression and less likely to have a preterm birth than participants using other forms of ART.
September 10, 2022
Investigators noted 2 distinct phases of HIV virus levels, meaning any infected cells that survive treatment can become latent, only to reignite HIV infection after antiretroviral therapy is stopped.
September 09, 2022
September 08, 2022
Texas judge Reed O’Connor ruled that requiring employers to cover the medical expense of HIV PrEP is a violation of religious freedom.
September 01, 2022
Taking into account the first PrEP pill was FDA approved in 2012, a clinician reflects on its significance and where the shortcomings of education and utility of it needs to be fortified.
August 22, 2022
The European Commission approved lenacapavir to treat multidrug-resistant HIV infection. The long-acting HIV treatment regimen will be marketed as Sunlenca and available in injection or tablet form.
August 16, 2022
The study was longitudinal in nature, comparing at-risk people who became infected with HIV to at-risk people who did not.
Invasive Nontyphoidal Salmonellosis: An Antimicrobial-Resistant Foe
Antibiotic Stewardship in Outpatient Care
Rapid, Reliable Diagnostic and PoC Tests Are Requisite for “Test to Treat"
HCV Not Associated With Myocarditis Risks for Young HIV Patients